Researching COVID to Enhance Recovery

SARS-CoV-2, the virus that causes COVD-19, can affect patients long after the initial phase of infection. This condition is called Post-Acute Sequelae of SARS-CoV-2 (PASC), more commonly known as “long COVID.” It involves new, relapsing, or continued symptoms of SARS-CoV-2, and can even result in organ dysfunction by immune response. The Researching COVID to Enhance Recovery (RECOVER) study aims to define the pathology, characteristics, and mechanisms of this disease. To date, it is the largest autopsy study to address long COVID among U.S. adults. This cross-sectional study involves subjects who died at least 15 days after initial SARS-CoV-2 infection. Through comprehensive autopsies, tissue samples, and medical history, scientists can further our understanding of long COVID as well as organ injury and disease. CVPath Institute mainly has a role in investigating cardiovascular outcomes of long COVID.

CVPath President and Chief Scientific Officer Aloke Finn contributed to this topic in a paper published in PLOS ONE, written by Troxel AB, et al.

Read about it here.